JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of JNJ-68179280 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-68179280
Other: Placebo

First Posted Date: 2021-04-14

Last Posted Date: 2023-07-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 94

Registration Number: NCT04844463

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of JNJ-67835989 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-67835989
Drug: Placebo

First Posted Date: 2021-04-14

Last Posted Date: 2024-05-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 109

Registration Number: NCT04844411

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Phase 1

Completed

Conditions: Fatty Liver Disease

Interventions: Drug: JNJ-75220795
Drug: Placebo

First Posted Date: 2021-04-14

Last Posted Date: 2023-08-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 55

Registration Number: NCT04844450

Locations: 🇺🇸
Research Centers of America, LLC, Hollywood, Florida, United States
🇺🇸
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Milvexian

First Posted Date: 2021-04-14

Last Posted Date: 2022-06-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 115

Registration Number: NCT04844424

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Phase 2

Completed

Conditions: Focal Onset Seizures

Interventions: Drug: JNJ-40411813
Drug: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 110

Registration Number: NCT04836559

Locations: 🇷🇺
Specialized clinical psychiatric hospital #1, Krasnodar, Russian Federation
🇷🇺
Clinical City Hospital #1, Moscow, Russian Federation
🇷🇺
Nizny Novgorod clinical psychiatric hospital 1, Nizny Novgorod, Russian Federation

and more 66 locations

A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Indomethacin
Diagnostic Test: Lactulose-mannitol

First Posted Date: 2021-03-29

Last Posted Date: 2021-06-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10

Registration Number: NCT04821323

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Conditions: Healthy

First Posted Date: 2021-03-26

Last Posted Date: 2021-03-26

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04817657

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ustekinumab

First Posted Date: 2021-03-25

Last Posted Date: 2022-02-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 300

Registration Number: NCT04816513

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Leukemias
Acute Myeloid Leukemia

Interventions: Drug: Bleximenib

First Posted Date: 2021-03-23

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 400

Registration Number: NCT04811560

Locations: 🇨🇳
West China Hospital Si Chuan University, Chengdu, China
🇨🇳
Nanfang Hospital of Southern Medical Hospital, Guangzhou, China
🇮🇱
Sheba Medical Center, Ramat Gan, Israel

and more 61 locations

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Phase 3

Active, not recruiting

Conditions: X-Linked Retinitis Pigmentosa

First Posted Date: 2021-03-11

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 97

Registration Number: NCT04794101

Locations: 🇨🇭
Universite de Lausanne, Hopital ophtalmique Jules-Gonin, Lausanne, Switzerland
🇬🇧
NHS Lothian, Edinburgh, United Kingdom
🇺🇸
Shiley Eye Institute Jacobs Retina Center, La Jolla, California, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy